Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III TrialPUJADE-LAURAINE, Eric; HILPERT, Felix; PEREIRA, Deolinda et al.Journal of clinical oncology. 2014, Vol 32, Num 13, pp 1302-1308, issn 0732-183X, 7 p.Article

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian CancerSTOCKLER, Martin R; HILPERT, Felix; SORIO, Roberto et al.Journal of clinical oncology. 2014, Vol 32, Num 13, pp 1309-1316, issn 0732-183X, 8 p.Article

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients : A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development GroupJOERGER, Markus; HUITEMA, Alwin D. R; SLEEBOOM, Henk P et al.Clinical cancer research. 2007, Vol 13, Num 21, pp 6410-6418, issn 1078-0432, 9 p.Article

Phase II study of XR5000 (DACA), an inhibitor of topoidomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerDITTRICH, Christian; DIERAS, Veronique; KERBRAT, Pierre et al.Investigational new drugs. 2003, Vol 21, Num 3, pp 347-352, issn 0167-6997, 6 p.Article

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III TrialPIGNATA, Sandro; SCAMBIA, Giovanni; VERNAGLIA LOMBARDI, Alessandra et al.Journal of clinical oncology. 2011, Vol 29, Num 27, pp 3628-3635, issn 0732-183X, 8 p.Article

Uterine cervical carcinoma : Role of matrix metalloproteinases (Review)LIBRA, Massimo; SCALISI, Aurora; VELLA, Nadia et al.International journal of oncology. 2009, Vol 34, Num 4, pp 897-903, issn 1019-6439, 7 p.Article

Population pharmacokinetics and pharmacodynamics of oral etoposideTOFFOLI, Giuseppe; CORONA, Giuseppe; SORIO, Roberto et al.British journal of clinical pharmacology. 2001, Vol 52, Num 5, pp 511-519, issn 0306-5251Conference Paper